These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35067346)

  • 1. Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins.
    Takahashi D; Wada H; Ogita M; Yasuda K; Nishio R; Takeuchi M; Shitara J; Tsuboi S; Dohi T; Suwa S; Miyauchi K; Daida H; Minamino T
    Am J Cardiol; 2022 Apr; 168():11-16. PubMed ID: 35067346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.
    Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H
    J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention.
    Takahashi N; Dohi T; Funamizu T; Endo H; Wada H; Doi S; Kato Y; Ogita M; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Shimada K
    J Cardiol; 2020 Jul; 76(1):25-29. PubMed ID: 32089480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.
    Matsushita K; Hibi K; Komura N; Kimura Y; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Kosuge M; Ebina T; Tamura K; Kimura K
    J Cardiol; 2020 Jul; 76(1):66-72. PubMed ID: 32037254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.
    Hao Y; Yang Y; Wang Y; Li J
    Curr Med Res Opin; 2022 Oct; 38(10):1663-1672. PubMed ID: 35575139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
    Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J
    JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome.
    Nakahashi T; Tada H; Sakata K; Yakuta Y; Tanaka Y; Nomura A; Gamou T; Terai H; Horita Y; Ikeda M; Namura M; Takamura M; Hayashi K; Yamagishi M; Kawashiri MA
    Heart Vessels; 2018 Jul; 33(7):695-705. PubMed ID: 29288404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease.
    Li Q; Chen Y; Yu L; Zhu L; Wang Z; Jiao S; Wu C; Tu Y; Wu Y; Guo Z; Gao Y; Zheng J; Sun Y
    Atherosclerosis; 2022 May; 349():204-210. PubMed ID: 35450749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome.
    Liu HH; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Dong Q; Qian J; Dou KF; Li JJ
    J Transl Med; 2022 May; 20(1):243. PubMed ID: 35619146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum apolipoprotein E levels predict residual cardiovascular risk in patients with chronic coronary syndrome undergoing first percutaneous coronary intervention and on-statin treatment.
    Fukase T; Dohi T; Chikata Y; Takahashi N; Endo H; Doi S; Nishiyama H; Kato Y; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Daida H; Minamino T
    Atherosclerosis; 2021 Sep; 333():9-15. PubMed ID: 34418683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.
    Zhu L; Fang Y; Gao B; Jin X; Zheng J; He Y; Huang J
    BMC Cardiovasc Disord; 2022 Nov; 22(1):474. PubMed ID: 36348286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.
    Konishi H; Miyauchi K; Kasai T; Tsuboi S; Ogita M; Naito R; Sai E; Fukushima Y; Katoh Y; Okai I; Tamura H; Okazaki S; Daida H
    Am J Cardiol; 2015 Jan; 115(2):157-60. PubMed ID: 25476560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Paradoxical Decrease in High-density Lipoprotein Cholesterol Levels After Statin Therapy on Major Adverse Cardiovascular Events in Patients with Stable Angina Pectoris.
    Hirayama K; Ota T; Harada K; Shibata Y; Tatami Y; Harata S; Kawashima K; Kunimura A; Shimbo Y; Takayama Y; Kawamiya T; Yamamoto D; Osugi N; Suzuki S; Ishii H; Murohara T
    Clin Ther; 2017 Feb; 39(2):279-287. PubMed ID: 28034517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.
    Zhong Z; Hou J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Lipids Health Dis; 2019 Feb; 18(1):40. PubMed ID: 30711009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention.
    Suwa S; Ogita M; Takahashi N; Wada H; Dohi T; Kasai T; Okazaki S; Shimada K; Miyauchi K; Bujo H; Daida H
    Int Heart J; 2020 May; 61(3):470-475. PubMed ID: 32350212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nonfasting triglycerides/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins.
    Matsumoto I; Misaki A; Kurozumi M; Nanba T; Takagi Y
    J Cardiol; 2018 Jan; 71(1):10-15. PubMed ID: 28916255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome.
    Li J; Wang H; Tian J; Chen B; Du F
    Medicine (Baltimore); 2018 Jul; 97(28):e11517. PubMed ID: 29995820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
    Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG
    J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome　- A Post Hoc Secondary Analysis of STOPDAPT-2 ACS.
    Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Natsuaki M; Yamaji K; Ogita M; Suwa S; Isawa T; Domei T; Ando K; Tatsushima S; Watanabe H; Oya M; Kadota K; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Kimura T;
    Circ J; 2023 Apr; 87(5):657-668. PubMed ID: 36477579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.